QCMD
Quality Control for Molecular Diagnostics

MOLECULAR EQA SOLUTIONS FOR SARS-COV-2 (COVID-19)



RANDOX

QCMD is a world leading EQA / Proficiency Testing (PT) provider, dedicated to improving the quality of molecular diagnostic assays used in the detection of infectious diseases. With an extensive database of over 2000 participants in over 100 countries, QCMD is one of the largest providers of molecular EQA in the field of infectious disease testing.

Randox offer two QCMD EQA programmes for SARS-CoV-2 (COVID-19). Each programme is designed to evaluate a laboratories ability to detect SARS-CoV-2 (COVID-19) using routine molecular methods and will provide an opportunity to assess performance against an international peer group.

Why Choose QCMD?

WHOLE PATHOGEN

The availability of whole pathogen samples containing the entire viral genome, ensures compatibility with the majority of commercial & in-house assays targeting the CDC and WHO consensus sequences.

MONITOR THE ENTIRE TESTING PROCESS

EQA samples are designed to mimic the patient sample and assess the full testing process from extraction to amplification and detection.

COMPREHENSIVE REPORTS

An individual report is received after each challenge, summarising laboratory performance in comparison to an international peer group.

ONLINE EQA MANAGEMENT SYSTEM

IT EQA Management System (ITEMS) provides an online tool to easily manage all EQA activities from programme registration to submission of results and provision of EQA reports.

NOT INFECTIOUS

Samples containing SARS-CoV-2 are inactivated and not infectious ensuring safe handling of material.

EQA Programmes

SARS-COV-2 EQA

The SARS-CoV-2 programme is designed to assess the ability of laboratories to detect SARS-CoV-2 at clinically relevant levels, near the Limit of Detection (LOD) and to assess the specificity of the assay in the presence of other coronaviruses. Four flexible participation options are available comprising 5 samples per challenge.

FEATURE	Available Format(s)			
Catalogue Number	**QAV204215_A**	**QAV204215_B**	**QAV204215_C**	**QAV204215_D**
Number of Challenges	1	1	1	1
Number of Samples per Challenge	5	5	5	5
Distribution / Testing Period	Q1	Q2	Q3	Q4

SPECIFICATIONS

SAMPLE NA TARGET SOURCE – Cultured and/or clinical material

TARGET RANGE – Covers the clinical range

MATRIX – Transport Medium

SAMPLE VOLUME – 1 ml

ANALYSIS TYPE – Qualitative

FORMAT – Liquid Frozen

ACCREDITED - Accredited to ISO17043



RESPIRATORY I PLUS (RESPIPLUS)

The RESPIplus EQA programme covers SARS-CoV-2 in addition to other respiratory pathogens including Influenza A, Influenza B and Respiratory Syncytial Virus (RSV) and is ideal for laboratories using multiplex and/or cartridge based molecular systems. The programme is designed to assess the ability of molecular workflows in the detection and differentiation of SARS-CoV-2 in combination with other respiratory pathogen targets.

FEATURE	Available Format(s)
Catalogue Number	**QAM204216_1**
Number of Challenges	1
Number of Samples per Challenge	10
Distribution / Testing Period	Q3

SPECIFICATIONS

SAMPLE NA TARGET SOURCE – Cultured and/or clinical material

TARGET RANGE – Covers the clinical range

MATRIX – Transport Medium

SAMPLE VOLUME – 1 ml

ANALYSIS TYPE – Qualitative

FORMAT – Liquid Frozen

RANDOX

Randox is a non-exclusive distribution partner of QCMD within selected countries. Contact your regional representative or **marketing@randox.com** for more details.